At the news
? BEARISHIMPACT 5/10 8-K filed Feb 25, 2026 at 07:11 ET
Ironwood Pharmaceuticals reported full-year 2025 revenue of $296 million, down from $351.4 million in 2024, with GAAP net income of $24 million and adjusted EBITDA of $138 million. Despite declining revenue and profits, the company reiterated strong 2026 guidance with expected total revenue of $450-$475 million and adjusted EBITDA exceeding $300 million, driven by improved net pricing and continued expense discipline. LINZESS demand grew 11% year-over-year in 2025.
- Full-year 2025 revenue was $296.2 million, down 15.7% from $351.4 million in 2024
- GAAP net income was $24 million in 2025, up from $0.9 million in 2024, but driven by one-time factors
- Adjusted EBITDA was $138.1 million in 2025, up slightly from $129.4 million in 2024
- LINZESS U.S. net sales declined 6% to $864.5 million in 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access